Evidence map›Paper›PMID 40610259›Full record

ArticleTrends in biotechnology2025

Vector-free intra-airway in vivo epigenetic editing.

Naohiro Yano, Mohankumar Ramar, David J Gregory, Alexey V Fedulov

Abstract read
In one paragraph

Article in Trends in biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Advances and clinical potential of epigenome editing.Cellular and molecular life sciences : CMLS · 2026
    Review
  2. Epigenetic editing: from concept to clinic.Nature reviews. Drug discovery · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Naohiro YanoMedical School of Brown University, Division of Surgical Research, Department of Surgery, Rhode Island Hospital, NAB B001. 593 Eddy Street, Providence, RI 02903, USA.
Mohankumar RamarMedical School of Brown University, Division of Surgical Research, Department of Surgery, Rhode Island Hospital, NAB B001. 593 Eddy Street, Providence, RI 02903, USA.
David J GregoryMedical School of Brown University, Division of Surgical Research, Department of Surgery, Rhode Island Hospital, NAB B001. 593 Eddy Street, Providence, RI 02903, USA.
Alexey V FedulovMedical School of Brown University, Division of Surgical Research, Department of Surgery, Rhode Island Hospital, NAB B001. 593 Eddy Street, Providence, RI 02903, USA. Electronic address: alexey@brown.edu.

Funding

Tracking and Evaluation CoreU54GM115677 · NIGMS · BROWN UNIVERSITY · PI TOVAR, ALISON · 2016 to 2025
$45.0M
Microbiome in Asthma Induced by Environmental Particle ExposureR01ES030227 · NIEHS · J. CRAIG VENTER INSTITUTE, INC. · PI FEDULOV, ALEXEY V, GONZALEZ-JUARBE, NORBERTO · 2019 to 2023
$3.4M
Targeted epigenetic activation of fibroblast genes in pulmonary fibrosisR21ES023936 · NIEHS · BRIGHAM AND WOMEN'S HOSPITAL · PI FEDULOV, ALEXEY V · 2015 to 2016
$488k
Epigenetic editor therapeuticsR41GM157863 · NIGMS · EPIGENTER, LLC · PI FEDULOV, ALEXEY V · 2025 to 2025
$299k
NIEHS NIH HHS R01 ES030227NIEHS NIH HHS R21 ES023936NIGMS NIH HHS R41 GM157863NIGMS NIH HHS U54 GM115677
6 · The paper itself

Abstract

Targeted, promoter-specific removal of DNA methylation marks is emerging as a promising strategy for experimental and therapeutic regulation of gene expression. Research to date has relied largely on the expression of transgene-encoded epigenetic editor constructs in target cells. While effective for in vitro demonstrations, alternative approaches are needed for greater translatability to humans. Here, we describe the design of recombinant, gene-targeted epigenetic editor proteins that are directly taken up by mouse lung cells following administration in vivo without transgenesis, vectors, or packaging tools. Proteins are targeted to their intended promoter using either dCas9 or artificial zinc finger domains, and thymine-DNA-glycosylase (TDG) and ten-eleven translocation proteins (Tet) catalytic domains mediate specific demethylation. Results demonstrate intranuclear arrival of epigenetic editors in vitro and in mice, local DNA demethylation, and resulting highly gene-specific derepression of the transcriptional response, which confers sensitivity to interferon (IFN) stimulation. Therefore, this study provides proof of principle for vector-free, targeted promoter demethylation in vivo.

Indexed as

Epigenesis, GeneticGene EditingAnimalsDNA MethylationEpigenome EditingHumansLungMicePromoter Regions, GeneticaerosolCxcl11demethylationepigenetic editingfusion demethylaseintra-airwaypulmonaryvector-free

Identifiers

PMID40610259
PMCPMC12233164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.